OSI-754 manufacturers
- CP-609754
-
- $50.00 / 1mg
-
2026-05-11
- CAS:1190094-64-4
- Min. Order:
- Purity: 99.87%
- Supply Ability: 10g
- CP-609754
-
- $1.00 / 1G
-
2018-07-23
- CAS:1190094-64-4
- Min. Order: 1MG
- Purity: >98%
- Supply Ability: 100G
|
| | OSI-754 Basic information |
| Product Name: | OSI-754 | | Synonyms: | OSI-754;CP 609754;LNK 754;CP-609754 (OSI754);6-[(R)-(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-4-(3-ethynylphenyl)-1-methylquinolin-2-one;2(1H)-Quinolinone, 6-[(R)-(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-;CP-609754(OS1754);CP-609754 (OSI754, LNK 754) | | CAS: | 1190094-64-4 | | MF: | C29H22ClN3O2 | | MW: | 479.96 | | EINECS: | | | Product Categories: | | | Mol File: | 1190094-64-4.mol |  |
| | OSI-754 Chemical Properties |
| Boiling point | 702.4±60.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (208.35 mM; Need ultrasonic) | | pka | 12.28±0.29(Predicted) | | form | Solid | | color | Off-white to yellow | | InChI | InChI=1/C29H22ClN3O2/c1-4-19-6-5-7-20(14-19)24-16-28(34)33(3)26-13-10-22(15-25(24)26)29(35,27-17-31-18-32(27)2)21-8-11-23(30)12-9-21/h1,5-18,35H,2-3H3/t29-/s3 | | InChIKey | JAHDAIPFBPPQHQ-NNFJEGBSNA-N | | SMILES | N1(C)C2=C(C=C([C@@](C3=CC=C(Cl)C=C3)(O)C3N(C)C=NC=3)C=C2)C(C2=CC=CC(C#C)=C2)=CC1=O |&1:6,r| |
| | OSI-754 Usage And Synthesis |
| Uses | CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL[1]. CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | | in vivo | CP-609754 (CP-609,754) has antitumor activity against 3T3 H-ras (61L) tumors in vivo[1].
With twice daily oral dosing of CP-609754, tumor regression is achieved with a dose of 100 mg/kg; the ED50 for tumor growth inhibition is 28 mg/kg[1].
With continuous i.p. infusion of CP-609754, tumor growth is inhibited by >50%, and tumor farnesyltransferase activity inhibited by >30% in mice in which the plasma concentration of CP-609754 is maintained above 118 ng/mL[1]. | | References | [1] Stacy L Moulder, et al. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004 Nov 1;10(21):7127-35. DOI:10.1158/1078-0432.CCR-04-0901 |
| | OSI-754 Preparation Products And Raw materials |
|